Other
Journal
Recent Headlines
Friday, May 17
Study: Depression Doubles Stroke Risk in Middle-Aged Women
Breast Cancer Drug, EndoTAG-1, Shows Promise in Phase II Trial
Nanotechnology Could Help Fight Diabetes, Scientists Say
Positive Phase III Results for Myelofibrosis Treatment
Physical and Emotional Impairments Often Untreated in Cancer Patients
Thursday, May 16
Researchers Identify U.S. ‘Hotspots’ for Infection and Sepsis-Related Mortality
Arthritis Drug Simponi (Golimumab) Gets Expanded Indication for Ulcerative Colitis
FDA Approves Radium Drug Xofigo for Metastatic Prostate Cancer
Positive Phase III Data for New Leukemia Drug, Obinutuzumab
AHA Report: Risk of Hospital Readmission Prolonged After Heart Attack, Heart Failure
Wednesday, May 15
FDA Approves Diagnostic Test for Lung Cancer
Study: Treatment With Two Osteoporosis Drugs Better Than Either Drug Alone
Scientists Develop ‘Magic Bullet’ for Acute Lung Injury
Positive Phase II Results Reported for Ovarian Cancer Vaccine
Administration Allocates $1 Billion for ‘Health Care Innovation Awards’
Tuesday, May 14
Flu in Pregnancy May Quadruple Child's Risk for Bipolar Disorder
Saturday, May 11
Advance Directives Can Reduce End-of-Life Medical Costs, Authors Say
Liver Transplantation for Hepatocellular Carcinoma in HIV-Infected Patients
Cocaine Vaccine Passes Key Hurdle
Thursday, May 9
FDA Alert: Lack of Sterility Assurance for Drug Products From ‘The Compounding Shop’
Wednesday, May 8
All Hospitals Should Require Drug, Alcohol Tests for Physicians
Report: Market for Pancreatic Cancer Therapies Expected to Double to $1.3 Billion Over Next Decade
CDC: Only Half of Americans With Hepatitis C Are Properly Tested
New Vaccine Candidate for Deadly H7N9 Flu Virus
Administration Offers Consumers a Look at Hospital Charges
Tuesday, May 7
AHA Statement: Understanding Heart Patients’ Quality of Life Can Improve Outcomes
FDA Warns Against Use of Migraine Prevention Drugs in Pregnant Women
Alzheimer’s Drug Fails Phase III Study
Survey: Prescription Drug Costs Among Top Concerns for Medicare Beneficiaries
New Lung Cancer Guidelines Recommend Screening for High-Risk Individuals
Monday, May 6
FDA Approves Liptruzet (Ezetimibe/Atorvastatin) to Lower Cholesterol
Report: State Spending Could Have ‘Huge Impact’ on Implementation of Health Care Law
Physicians Expect Xtandi (Enzalutamide) to Become Treatment Leader for Metastatic Prostate Cancer
New Guidelines for Managing Fibromyalgia
FDA Warning: Nonproprietary Name for Breast Cancer Drug Could Cause Medication Errors
Friday, May 3
Simple Blood Test Tracks Tumor Evolution in Cancer Patients
CDC: Only One in Five Adults Meet Overall Physical Activity Guidelines
Sublingual Sufentanil More Effective Than IV Morphine in Phase III Trial
New Clinical Guideline on Prostate Cancer Screening
FDA Approves Wider Indication for Sustiva (Efavirenz) in HIV-Infected Pediatric Patients
Thursday, May 2
Ofatumumab/Bendamustine Combo Shows Promise in Leukemia Patients
Study: Statins May Reduce Risk of Death From Prostate Cancer
Positive Phase III Results With Aclidinium/Formoterol in COPD
Report: All-Oral, IFN-Free Regimen Is Major Unmet Need in HCV Patients
FDA Advisors Give ‘Thumbs Down’ to Renal Cancer Drug, Tivozanib
Wednesday, May 1
Arthritis Drug Actemra (Tocilizumab) Gets Expanded Indication
Poll: Much of the Public Still Confused About Affordable Care Act
FDA Rejects Opioid-Dependence Drug Probuphine (Buprenorphine)
Report: 'Medical Homes' May Be Answer to Overburdened Health Care System
Tuesday, Apr 30
FDA Approves Kcentra (Prothrombin Complex Concentrate) for Urgent Reversal of Anticoagulation
Government Report: Health Care Costs Expected to Erase State, Local Budget Improvements
Women Smokers May Have Greater Risk for Colon Cancer Than Men
Task Force Recommends Routine HIV Testing for All Adults
Labeling Updates for Anticoagulant Drug Pradaxa (Dabigatran)
Monday, Apr 29
Senate Bill Would Give FDA Greater Authority Over Some Compounding Pharmacies
Positive Phase III Results for Pneumococcal Vaccine, Prevenar 13, in Adults
Survey: Ulcerative Colitis Drug Vedolizumab May Offer Better Remission Rates Versus Infliximab
